Astra Zeneca/Starpharma Combination Potential Blockbuster Anticancer Drug Approved For Clinical Trials By FDA
Keith Williams Conclusion
I keep writing about Starpharma as I think it is a really interesting company that, being Australian, slips below the radar. It deserves more attention, albeit by risk-comfortable investors looking for substantial upside in a reasonably short time frame. While the company hasn't disclosed the milestone payment by Astra Zeneca for AZD0466 entering the clinic, I suspect it will be significant and support Starpharma's already strong cash position, which will help it fund the 3 other in-house DEP programs that are in clinical trials. Starpharma has foreshadowed that AZN0466 will enter clinical trials before the end of this calendar year. Perhaps that might also wake up interest in the company?
Astra Zeneca/Starpharma Combination Potential Blockbuster...
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $43.90M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 11.5¢ | 10.0¢ | $110.6K | 1.006M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 83046 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 30000 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| SPL (ASX) Chart |